Dr. Vanderlugt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
2152 Walker Trail
Kalamazoo, MI 49009Phone+1 269-370-5180- Is this information wrong?
Education & Training
Western Michigan University Homer Stryker MD School of MedicineResidency, Internal Medicine, 1979 - 1981
Spectrum Health/Michigan State UniversityInternship, Internal Medicine, 1978 - 1979
University of Michigan Medical SchoolClass of 1978
Certifications & Licensure
MI State Medical License 1979 - 2021
Clinical Trials
- Safety and Pharmacokinetics Study of CARD-024 in Healthy Subjects Start of enrollment: 2011 Sep 01
- Study of CXA-10 in Healthy Volunteers Start of enrollment: 2014 Apr 01
Publications & Presentations
PubMed
- 1 citationsPharmacokinetics and Bioequivalence of Branded and Generic Formulations of Dofetilide 0.5-mg Capsules After Single-Dose Administration in Healthy Subjects.James T. VanderLugt, Charles Bon, Dean Knuth, Rhonda Schreiber, Michael D. Ruff> ;Clinical Pharmacology in Drug Development. 2018 Mar 1
- 34 citationsAn Evaluation of MSDC-0160, A Prototype mTOT Modulating Insulin Sensitizer, in Patients with Mild Alzheimer's DiseaseRaj C. Shah, Dawn C. Matthews, Randolph D. Andrews, Ana W. Capuano, Debra A. Fleischman, James T. VanderLugt, Jerry R. Colca> ;Current Alzheimer Research. 2014 Jun 30
- Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer.Colca JR, VanderLugt JT, Adams WJ, Shashlo A, McDonald WG, Liang J, Zhou R, Orloff DG> ;Clin. Pharmacol. Ther.. 2013-04-01
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
